Developing Cell-Based Therapies for RPE-Associated Degenerative Eye Diseases

Area of Science:

• Ophthalmology
• Regenerative Medicine
• Genetics

Background:

• Retinal degenerative diseases, including age-related macular dystrophy (AMD) and retinitis pigmentosa (RP), are leading causes of blindness globally.
• These conditions result in irreversible vision loss due to photoreceptor cell death, representing a significant unmet medical need.
• While most inherited retinal disease (IRD) genes affect photoreceptors, some impact the retinal pigment epithelium (RPE), crucial for photoreceptor health.

Purpose of the Study:

• To review past and current cell-based strategies for treating RPE-associated degenerative eye diseases.
• To highlight the potential of cell therapies in preventing photoreceptor death and vision loss.
• To discuss the development of innovative eye-care strategies for retinal dystrophies.

Main Methods:

• Review of scientific literature on cell-based strategies for RPE-associated retinal diseases.
• Analysis of proof-of-concept studies in animal models demonstrating safety and efficacy of cell engraftment.
• Examination of ongoing drug development pipelines for cell-based treatments.

Main Results:

• Cell-based approaches have shown promise in supporting RPE function and providing trophic support to photoreceptors in preclinical models.
• Animal studies indicate the safety and efficacy of therapeutic cell engraftment for retinal repair.
• Several cell-based therapies are advancing through the drug development pipeline, aiming for clinical application.

Conclusions:

• Inherited retinal dystrophies are attractive models for cell therapy due to ocular accessibility and immune privilege.
• Cell-based strategies offer a potential therapeutic avenue to replace, regenerate, or repair damaged RPE tissue.
• Innovative cell-based treatments are being developed to address the unmet medical need in RPE-associated degenerative eye diseases.